Marc Goodman
Stock Analyst at Leerink Partners
(4.57)
# 232
Out of 5,241 analysts
100
Total ratings
57.32%
Success rate
24.67%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Outperform | $160 → $170 | $158.42 | +7.31% | 5 | Apr 22, 2026 | |
| MANE Veradermics | Maintains: Outperform | $75 → $90 | $99.72 | -9.75% | 2 | Apr 22, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $215 → $225 | $228.77 | -1.65% | 6 | Apr 22, 2026 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $40 → $35 | $18.62 | +87.97% | 2 | Apr 22, 2026 | |
| DFTX Definium Therapeutics | Maintains: Outperform | $23 → $30 | $20.99 | +42.93% | 1 | Apr 22, 2026 | |
| SGP SpyGlass Pharma | Initiates: Outperform | $42 | $23.21 | +80.96% | 1 | Mar 3, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $227.72 | -9.98% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $1.84 | +334.78% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $28.73 | +4.42% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $2.63 | +90.11% | 1 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $29.66 | +14.63% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $50 | $8.76 | +470.78% | 7 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $10 | $13.29 | -24.73% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $10 → $1 | $6.90 | -85.51% | 3 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $7.34 | +335.97% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $143.00 | -82.52% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $6.50 | +207.69% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $192.95 | +60.66% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $54.39 | -15.43% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $21.40 | -1.87% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.79 | +258.42% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $37.48 | -27.96% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $1.68 | +792.86% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $494.28 | -45.38% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $210.39 | -54.37% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.00 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $111.38 | -39.85% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $10.61 | +823.66% | 7 | Oct 5, 2017 |
Neurocrine Biosciences
Apr 22, 2026
Maintains: Outperform
Price Target: $160 → $170
Current: $158.42
Upside: +7.31%
Veradermics
Apr 22, 2026
Maintains: Outperform
Price Target: $75 → $90
Current: $99.72
Upside: -9.75%
Jazz Pharmaceuticals
Apr 22, 2026
Maintains: Outperform
Price Target: $215 → $225
Current: $228.77
Upside: -1.65%
Denali Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $40 → $35
Current: $18.62
Upside: +87.97%
Definium Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $23 → $30
Current: $20.99
Upside: +42.93%
SpyGlass Pharma
Mar 3, 2026
Initiates: Outperform
Price Target: $42
Current: $23.21
Upside: +80.96%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $227.72
Upside: -9.98%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $1.84
Upside: +334.78%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $28.73
Upside: +4.42%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $2.63
Upside: +90.11%
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $29.66
Upside: +14.63%
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $8.76
Upside: +470.78%
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $13.29
Upside: -24.73%
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $6.90
Upside: -85.51%
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $7.34
Upside: +335.97%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $143.00
Upside: -82.52%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.50
Upside: +207.69%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $192.95
Upside: +60.66%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $54.39
Upside: -15.43%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $21.40
Upside: -1.87%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.79
Upside: +258.42%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $37.48
Upside: -27.96%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $1.68
Upside: +792.86%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $494.28
Upside: -45.38%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $210.39
Upside: -54.37%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $57.00
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $111.38
Upside: -39.85%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $10.61
Upside: +823.66%